KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday

Key Points

• KALA BIO is expected to report Q4 2025 results before the market opens on March 26, with analysts forecasting earnings of -$0.32 per share and an earnings call scheduled for March 27 at 9:30 AM ET.
• Shares opened at around $0.25 amid extreme volatility (12‑month range $0.23–$20.60) and the company has a market cap of about $230 million.
• Analyst sentiment is mixed: the average rating is Hold with an average target of $20.38, Weiss Ratings reiterated a "sell (e+)," and roughly 24.6% of the stock is owned by hedge funds and other institutions.

KALA BIO (NASDAQ:KALA - Get Free Report) is expected to post its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect KALA BIO to post earnings of ($0.32) per share for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

KALA BIO Trading Up 0.2%

NASDAQ KALA opened at $0.25 on Thursday. The company's 50-day moving average price is $0.45 and its 200-day moving average price is $2.93. The stock has a market cap of $230.11 million, a PE ratio of -0.04 and a beta of -2.37. KALA BIO has a 12 month low of $0.23 and a 12 month high of $20.60.

Institutional Investors Weigh In On KALA BIO

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of KALA BIO by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after buying an additional 1,534 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of KALA BIO in the second quarter valued at about $62,000. Virtu Financial LLC purchased a new stake in KALA BIO in the fourth quarter worth about $48,000. Jane Street Group LLC bought a new position in KALA BIO during the 4th quarter worth about $80,000. Finally, Woodline Partners LP bought a new position in KALA BIO during the 1st quarter worth about $1,483,000. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of KALA BIO in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, KALA BIO currently has an average rating of "Hold" and an average target price of $20.38.

About KALA BIO

KALA Bio NASDAQ: KALA is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company's proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.

Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.